Compare Champions Oncology, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 87 Million (Micro Cap)
36.00
NA
0.00%
-1.65
58.30%
20.81
Revenue and Profits:
Net Sales:
17 Million
(Quarterly Results - Jan 2026)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.84%
0%
-18.84%
6 Months
-12.54%
0%
-12.54%
1 Year
-39.02%
0%
-39.02%
2 Years
12.26%
0%
12.26%
3 Years
46.5%
0%
46.5%
4 Years
-30.9%
0%
-30.9%
5 Years
-55.61%
0%
-55.61%
Champions Oncology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.31%
EBIT Growth (5y)
33.35%
EBIT to Interest (avg)
-1.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
6.14
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
43.24%
ROCE (avg)
40.85%
ROE (avg)
24.39%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
20.81
EV to EBIT
32.44
EV to EBITDA
20.13
EV to Capital Employed
-29.33
EV to Sales
1.37
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
58.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Jan 2026
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 5 Schemes (3.02%)
Foreign Institutions
Held by 13 Foreign Institutions (0.75%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jan'26 - QoQ
Jan'26
Oct'25
Change(%)
Net Sales
16.60
15.00
10.67%
Operating Profit (PBDIT) excl Other Income
0.20
0.50
-60.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.30
0.20
-250.00%
Operating Profit Margin (Excl OI)
-11.30%
12.30%
-2.36%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jan 2026 is 10.67% vs 7.14% in Oct 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jan 2026 is -250.00% vs 140.00% in Oct 2025
Annual Results Snapshot (Consolidated) - Apr'25
Apr'25
Apr'24
Change(%)
Net Sales
56.90
50.20
13.35%
Operating Profit (PBDIT) excl Other Income
6.50
-5.10
227.45%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.70
-7.30
164.38%
Operating Profit Margin (Excl OI)
85.10%
-138.00%
22.31%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2025 is 13.35% vs -6.86% in Apr 2024
Consolidated Net Profit
YoY Growth in year ended Apr 2025 is 164.38% vs -37.74% in Apr 2024
About Champions Oncology, Inc. 
Champions Oncology, Inc.
Pharmaceuticals & Biotechnology
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.
Company Coordinates 
Company Details
855 N Wolfe St Ste 619 , BALTIMORE MD : 21205-1511
Registrar Details






